The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.60

Today's change-0.02 -1.23%
Updated May 4 3:21 PM EDT. Delayed by at least 15 minutes.
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $1.60

Today's change-0.02 -1.23%
Updated May 4 3:21 PM EDT. Delayed by at least 15 minutes.

Arena Pharmaceuticals Inc down (U.S.)$0.02

Arena Pharmaceuticals Inc is lower today, dropping (U.S.)$0.02 or 1.23% to (U.S.)$1.60. Over the last five days, shares have lost 10.61% and are down 15.79% for the last year to date. This security has underperformed the S&P 500 by 59.88% during the last year.

Key company metrics

  • Open(U.S.) $1.62
  • Previous close(U.S.) $1.62
  • High(U.S.) $1.68
  • Low(U.S.) $1.58
  • Bid / Ask(U.S.) $1.59 / (U.S.) $1.60
  • YTD % change-15.79%
  • Volume898,181
  • Average volume (10-day)1,695,108
  • Average volume (1-month)1,673,254
  • Average volume (3-month)2,052,771
  • 52-week range(U.S.) $1.30 to (U.S.) $5.12
  • Beta-0.57
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.45
Updated May 4 3:21 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-281.74%

Although this company's net profit margin is negative, it is above the industry average and implies that Arena Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue89912
Total other revenue--------
Total revenue89912
Gross profit5669
Total cost of revenue3334
Total operating expense37343634
Selling / general / administrative10998
Research & development20222422
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)4------
Other operating expenses, total--------
Operating income-29-25-27-22
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-30-26-27-24
Income after tax-30-26-27-24
Income tax, total------0
Net income-30-26-27-24
Total adjustments to net income--------
Net income before extra. items-30-26-27-24
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-30-26-27-24
Inc. avail. to common incl. extra. items-30-26-27-24
Diluted net income-30-26-27-24
Dilution adjustment--0--0
Diluted weighted average shares243242242236
Diluted EPS excluding extraordinary itemsvalue per share-0.13-0.11-0.11-0.10
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.11-0.11-0.11-0.10